June 03, 2026 21:55 ET | Source: BrightSpring Health Services, Inc. LOUISVILLE, Ky., June 03, 2026 (GLOBE NEWSWIRE) -- BrightSpring…
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S. June 03, 2026…
CHAPEL HILL, N.C., June 03, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other…
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate…
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support…
Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to…
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year…
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvalsAppointment strengthens confidence…
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a…
June 01, 2026 08:05 ET | Source: Cellectar Biosciences, Inc. Approximately 80% Major Response Rate and Duration of Response Exceeding…